Kymera Therapeutics, Inc. (KYMR)

Kymera Therapeutics, Inc.'s Q·Score is 5.6/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.1× debt-to-equity). Key area to monitor: currently unprofitable (-285% margin). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for KYMR is $137.73, based on ratings from 22 Wall Street analysts. This is 21.7% above the current price of $113.15. Price targets are forward-looking estimates and not guarantees of future performance.

Kymera Therapeutics, Inc. (KYMR) scores in line with sector averages on valuation metrics. The consensus analyst price target of $137.73 is 22% above the current price.

Kymera Therapeutics, Inc.'s next earnings report is expected on approximately November 3, 2026.

Kymera Therapeutics, Inc. has a net profit margin of -285.3%, indicating the company is currently operating at a net loss. Its gross margin stands at -257.7%, reflecting a more cost-intensive business model.

Kymera Therapeutics, Inc. is reporting strong year-over-year growth of 466.4%.

Kymera Therapeutics, Inc. has a debt-to-equity ratio of 0.05×, reflecting a very low debt-to-equity ratio, signalling a conservatively financed balance sheet. Its current ratio is 10.34×, indicating comfortable short-term liquidity.